CIK 0001531177
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Sight Sciences, Inc.
Sign in to watch- Ticker
- SGHT
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 800625749
- Phone
- +1 415-889-0550
- Business address
- 4040 CAMPBELL AVE,, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $652,777
- in 5 filings, $653K under 10b5-1 plans
Net −$652,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Badawi Paul −$268K President and CEO sold <1% of stake
- Bauerlein Alison −$224K Chief Operating Officer sold 4% of stake
- Badawi David −$71K Chief Technology Officer sold <1% of stake
- Rodberg James −$64K Chief Financial Officer sold 3% of stake
- Taylor Brenton −$26K EVP, Operations & R&D sold 1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-09 | O'Neil Shawn Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +72,300 | 72,300 | ||
| 2022-02-09 | Park Sam Boong Chief Operating Officer | Grant or award · Restricted Stock Units | +24,100 | 24,100 | ||
| 2022-02-09 | Park Sam Boong Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +96,400 | 96,400 | ||
| 2021-12-01 | Encrantz Staffan Director | Purchase | +27,716 | $21.43 | $594K | 3,835,228 |
| 2021-12-01 | Encrantz Staffan Director | Purchase | +123,931 | $22.36 | $2.8M | 3,959,159 |
| 2021-12-01 | Encrantz Staffan Director | Purchase | +62,959 | $22.92 | $1.4M | 4,022,118 |
| 2021-11-30 | Encrantz Staffan Director | Purchase | +72,135 | $19.44 | $1.4M | 3,655,707 |
| 2021-11-30 | Encrantz Staffan Director | Purchase | +94,969 | $20.40 | $1.9M | 3,750,676 |
| 2021-11-30 | Encrantz Staffan Director | Purchase | +56,836 | $20.96 | $1.2M | 3,807,512 |
| 2021-11-29 | Encrantz Staffan Director | Purchase | +84,254 | $18.84 | $1.6M | 3,581,372 |
| 2021-11-29 | Encrantz Staffan Director | Purchase | +2,200 | $19.06 | $42K | 3,583,572 |
| 2021-11-23 | Selnick Jesse Chief Financial Officer | Purchase | +10,000 | $18.44 | $184K | 2,229,568 |
| 2021-10-18 | Encrantz Staffan Director | Purchase | +527,048 | $24.00 | $12.6M | 3,497,118 |
| 2021-07-19 | D1 Capital Partners L.P. 10% owner | Conversion | +5,152,036 | 5,152,036 | ||
| 2021-07-19 | D1 Capital Partners L.P. 10% owner | Purchase | +700,000 | $24.00 | $16.8M | 5,852,036 |
| 2021-07-19 | D1 Capital Partners L.P. 10% owner | Conversion · Series E Convertible Preferred Stock | −1,890,395 | 0 | ||
| 2021-07-19 | D1 Capital Partners L.P. 10% owner | Conversion · Series F Convertible Preferred Stock | −685,623 | 0 | ||
| 2021-07-19 | KCK LTD. 10% owner | Conversion | +4,776,232 | 4,776,232 | ||
| 2021-07-19 | KCK LTD. 10% owner | Conversion · Series D Convertible Preferred Stock | −2,388,116 | 0 | ||
| 2021-07-19 | Selnick Jesse Chief Financial Officer | Conversion | +2,219,568 | 2,219,568 |
Page 14 of 16 · 302 trades